
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SVX-24
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : RA Capital Management
Deal Size : $110.0 million
Deal Type : Series D Financing
Details : SutroVax has generated preclinical proof of concept versus the standard of care vaccines and intends to advance SVX-XP into the clinic as a future successor to SVX-24.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 26, 2020
Lead Product(s) : SVX-24
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : RA Capital Management
Deal Size : $110.0 million
Deal Type : Series D Financing
